No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
CN Stock MarketDetailed Quotes
688363 Bloomage Biotechnology Corporation Limited
- 50.87
- +2.27+4.67%
Trading May 15 11:27 CST
24.50BMarket Cap748.09P/E (TTM)
52.30High48.24Low78.00KlotVolume48.58Open48.60Pre Close394.72MTurnover1.62%Turnover Ratio140.52P/E (Static)481.68MShares84.5952wk High3.54P/B24.50BFloat Cap42.5152wk Low58.32Limit Up481.68MShs Float313.10Historical High38.88Limit Down8.35%Amplitude42.51Historical Low0.38Dividend TTM50.61Avg Price26.19KlotAsk0.75%Div YieldTTM100Lot Size48.16KlotBid
Intraday
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Bloomage Biotechnology Corporation Limited (688363): Return to positive Net income for the parent company compared to the previous quarter,期待 management reform results.
In the first quarter of 2025, the net income attributable to the parent company increased quarter-on-quarter, and the business of biological active substances and medical terminal operations remained stable. The company achieved revenue of 1.078 billion yuan in the first quarter of 2025, a year-on-year decrease of 20.77%; it achieved net income attributable to the parent company.
Bloomage Biotechnology Corporation Limited (688363): Performance improved compared to Q4 2024, major changes in Global Strategy.
The company released its 25Q1 Earnings Reports, with performance meeting market expectations. In 25Q1, the company's revenue was 1.08 billion yuan, a year-on-year decline of 20.8%; the net income attributable to the parent company was 0.1 billion yuan, a year-on-year decline of 58.1%. The net income attributable to the parent company after deducting non-recurring items was 0.8.
Bloomage Biotechnology Corporation Limited (688363): Deepening reforms lead to short-term pressure, looking forward to a turning point in development in 2025.
Organizational management changes continue to pressure short-term performance, looking forward to the operational turning point in 2025. The company released its annual and quarterly reports: revenue of 5.371 billion yuan in 2024 (year-on-year -11.6%, the same below), and net income attributable to the parent company of 1.
Bloomage Biotechnology Corporation Limited (688363): The first domestic Class III device for water light products has been launched,期待皮肤科学创新转化业务变革成效落地.
The company announced its Q1 report for 2025: In Q1 2025, revenue was 1.078 billion yuan, a year-on-year decrease of 20.77%; net income attributable to shareholders was 0.102 billion yuan, a year-on-year decrease of 58.13%.
Bloomage Biotechnology Corporation Limited (688363): Transformation in progress, "Run Bai Yan·Bo Bo" has been approved to further enrich the medical beauty product matrix.
Event: The company released the Q1 2025 report, with revenue of 1.08 billion yuan for Q1 2025, a year-on-year decrease of 20.8%, and a net income attributable to the parent of 0.1 billion yuan, a year-on-year decrease of 58.1%. Comment: Innovation and transformation in skin science.
Huaxi Biotech 2025 First Quarter Report
Market Insights
Tariff Storm Hits: Hedge with ETFs? Tariff Storm Hits: Hedge with ETFs?
The U.S. has sparked a tariff storm, triggering global market volatility. When the market fluctuates violently, more investment opportunities often appear. Compared with choosing individual stocks, investing in ETFs of the broader market can more easily capture opportunities for market reversals.
Disclaimer: Among the U.S. stock market index ETFs: EFF, which is in the top 3 in terms of asset size among the fear index ETFs; the top 3 ETFs in terms of asset size among the S&P 500 index ETFs; and the corresponding leveraged ETFs; the top 4 ETFs in terms of asset size among the Nasdaq ETFs; and the top 3 ETFs in terms of asset size among the Dow Jones Index.
This presentation is for informational and educational use only and is not a recommendation or endorsement of any particular investment or investment strategy. Investment information provided in this content is general in nature, strictly for illustrative purposes, and may not be appropriate for all investors. It is provided without respect to individual investors' financial sophistication, financial situation, investment objectives, investing time horizon, or risk tolerance. You should consider the appropriateness of this information having regard to your relevant personal circumstances before making any investment decisions. Past investment performance does not indicate or guarantee future success. Returns will vary, and all investments carry risks, including loss of principal. FUTU makes no representation or warranty as to its adequacy, completeness, accuracy or timeline for any particular purpose of the above content.
Instutional holding and portfolio information provided is based data in 13f filings. The composition provided is updated on a significant delay and may be incomplete. It is not possible to replicate the timing or exact holdings and portfolios. The U.S. has sparked a tariff storm, triggering global market volatility. When the market fluctuates violently, more investment opportunities often appear. Compared with choosing individual stocks, investing in ETFs of the broader market can more easily capture opportunities for market reversals.
Disclaimer: Among the U.S. stock market index ETFs: EFF, which is in the top 3 in terms of asset size among the fear index ETFs; the top 3 ETFs in terms of asset size among the S&P 500 index ETFs; and the corresponding leveraged ETFs; the top 4 ETFs in terms of asset size among the Nasdaq ETFs; and the top 3 ETFs in terms of asset size among the Dow Jones Index.
This presentation is for informational and educational use only and is not a recommendation or endorsement of any particular investment or investment strategy. Investment information provided in this content is general in nature, strictly for illustrative purposes, and may not be appropriate for all investors. It is provided without respect to individual investors' financial sophistication, financial situation, investment objectives, investing time horizon, or risk tolerance. You should consider the appropriateness of this information having regard to your relevant personal circumstances before making any investment decisions. Past investment performance does not indicate or guarantee future success. Returns will vary, and all investments carry risks, including loss of principal. FUTU makes no representation or warranty as to its adequacy, completeness, accuracy or timeline for any particular purpose of the above content.
Instutional holding and portfolio information provided is based data in 13f filings. The composition provided is updated on a significant delay and may be incomplete. It is not possible to replicate the timing or exact holdings and portfolios.
Unlock Now
Discussing
中美大降關稅！如何抓住市場爆升機會？
中美關稅超預期降溫，市場迎來久違狂歡。5月12日下午，中方公佈中美日內瓦經貿會談聯合聲明，美方取消共計91%的加徵關稅，中方相應取消91%的反制關稅，美方暫停實施24%的「對等關稅」，中方相應暫停實施24%的反制關稅。聲明公佈後，港美股當日應聲暴漲，修復至關稅前水平。13日，特朗
Food流油
Apr 14 15:43
"Leaving the Group - Raising Taxes - Tweeting: The 'Money Making Strategy' of the Most Wild Gemini in Contemporary Times"
Investment Course
Choose stocks based on financial reports
Quickly master financial season learning guidelines
When the financial season comes, company stock prices are the most likely to rise and fall, and many excellent investors will see the financial season as a good
[2025.2] How should NVIDIA's performance be viewed? The key indicator to watch for short-term stock prices is this.
NVIDIA has been one of the best-performing Technology giants in the US stock market over the past two years, and since 2024, its stock price has experienced sig
How to view Tesla's performance in January 2025? Pay attention to these four key points.
It's earnings season for US stocks again. The performance of giant companies not only affects their own stock prices but also influences the overall trend of th